Yahoo Search Busca da Web

Resultado da Busca

  1. Há 4 dias · Despite extensive research and improvements in understanding colorectal cancer (CRC), its metastatic form continues to pose a substantial challenge, primarily owing to limited therapeutic options ...

  2. 10 de mai. de 2024 · Introduction. Colorectal cancer (CRC) is a molecularly heterogeneous disease [ 1, 2 ]. The heterogeneity of cell types involved in CRC carcinogenesis makes it difficult to elucidate cell lineages...

    • Jing Xiao
  3. Há 4 dias · This Review addresses the emerging focus on metastatic CRC (mCRC), which has historically been under-studied compared with primary CRC, and explores how the tumour microenvironment influences metastatic disease. Despite extensive research and improvements in understanding colorectal cancer (CRC), its metastatic form continues to pose a substantial challenge, primarily owing to limited ...

  4. 22 de mai. de 2024 · View PDF View EPUB. This report describes a case of BRAF V600E-mutated colorectal cancer with CNS metastases in which treatment with encorafenib, binimetinib and cetuximab was effective. There is limited information on the ability of encorafenib, binimetinib and cetuximab to enter the CNS.

  5. 25 de mai. de 2024 · However, cancer cells exhibit higher levels of aberrant hyperactivation of these components than healthy colonic mucosa cells. Overexpression of Notch pathways in cancers like colon cancer is linked to poor prognosis and therapeutic response. Notch signaling, which causes ALDH1A1 deacetylation, is associated with aggressive metastatic cancer.

  6. Há 3 dias · 3556 Background: Botensilimab (BOT) is an Fc-enhanced, multifunctional anti-CTLA-4 antibody with unique mechanisms of action. In microsatellite stable colorectal cancer (MSS CRC), previous I-O combinations have shown poorer responses in metastatic sites of disease outside of the lungs and lymph nodes, even in non-liver metastases (NLM) populations. Here we present updated efficacy data with ...